Thierry F Calandra - Infectious Diseases

Author Information

Thierry Calandra is a distinguished researcher in the field of infectious diseases, currently affiliated with the Infectious Diseases Service at the Centre Hospitalier Universitaire Vaudois and the University of Lausanne in Switzerland. His work predominantly focuses on critical areas such as sepsis, pneumonia, and COVID-19, with significant contributions to understanding immune responses and therapeutic interventions.

Research Contributions

Thierry Calandra has made substantial contributions to infectious disease research, with a particular emphasis on the immune response in sepsis and COVID-19. His recent work includes exploring the roles of cytokines like HGF and CXCL13 in predicting the severity and mortality of COVID-19, as well as studying the impact of antibiotic therapy timing on sepsis outcomes. His research on monocytic myeloid-derived suppressor cells in sepsis and pneumonia has provided insights into potential favorable outcomes, and his studies on SARS-CoV-2 seroprevalence and antibody responses have been pivotal during the ongoing pandemic.

Aliases

Thierry Calandra is also known by several aliases in academic publications, including T. Calandra, Th. Calandra, and Thierry F Calandra. These variations may appear across different journals and papers.

Publication and Citation Metrics

Metric	Value
Total Citations	43,664
h-index	95
Total Papers	350

Publications:

High levels of monocytic myeloid-derived suppressor cells are associated with favorable outcome in patients with pneumonia and sepsis with multi-organ failure

DOI: 10.1186/s40635-022-00431-0

Year: 2022

Low neutralizing antibody titers after asymptomatic or non-severe SARS-CoV-2 infection over a 6-month assessment period

DOI: 10.1016/j.jinf.2022.02.001

Year: 2022

SARS-CoV-2 seroprevalence in healthcare workers of a Swiss tertiary care centre at the end of the first wave: a cross-sectional study

DOI: 10.1136/bmjopen-2021-049232

Year: 2021

Impact of the Timeliness of Antibiotic Therapy on the Outcome of Patients with Sepsis and Septic Shock.

DOI: 10.1016/j.jinf.2021.03.003

Year: 2021

Sepsis Awareness at the University Hospital Level: A Survey-Based Cross-Sectional Study

DOI: 10.21203/rs.3.rs-1016400/v1

Year: 2021

The cytokines HGF and CXCL13 predict the severity and the mortality in COVID-19 patients

DOI: 10.1038/s41467-021-25191-5

Year: 2021

EORTC/MSGERC Definitions of Invasive Fungal Diseases: Summary of Activities of the Intensive Care Unit Working Group.

DOI: 10.1093/cid/ciaa1751

Year: 2021

HGF and CXCL13, Two Antagonizing Cytokines in Lung Inflammation and Fibrosis, Predict the Severity and the Mortality of COVID-19

DOI: 10.21203/RS.3.RS-241266/V1

Year: 2021

Initial antimicrobial management of sepsis

DOI: 10.1186/s13054-021-03736-w

Year: 2021

High-dimensional immune phenotyping of blood cells by mass cytometry in patients infected with hepatitis C virus.

DOI: 10.1016/j.cmi.2021.08.018

Year: 2021

What is the Future of the Global Fund?

How Does the CDC Monitor Infectious Diseases?

What Are Parasitic Infections?

How Does Direct Contact Transmission Occur?

Why is Hygiene Important in Infectious Diseases?

What are the Implications of Genomics for Treatment?

How Do Antimicrobial Treatments Affect Lipid Metabolism?

What Are the Challenges in Controlling Dengue?

What Are the Common Types of Infectious Diseases?

What Illnesses Do Adenoviruses Cause?

Partnered Content Networks

Relevant Topics